Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 166

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 166
---
 Lloyd M. Segal             |     |           — |     |             — |     | —                    |     |         — |
| Maria Koehler, M.D., Ph.D. |     |           — |     |             — |     | —                    |     |         — |
| Michael Zinda, Ph.D.       |     |   1,041,733 |     |       161,359 |     | —                    |     | 1,203,092 |

| (1) | Under relevant SEC rules, the Company is required to provide information in this table with respect to the                                                                                                      
 Company’s named executive officers, who, for these purposes, are the individuals whose compensation was required to be reported in the summary compensation table of the Company’s most recent proxy statement. |

| (2) | As described in more detail in the section titled “Potential Severance Payments and                                                                                                                                   
 Benefits,” the amounts in this column represent the cash severance payments that Dr. Zinda would be paid in the event he is terminated without “cause” or resigns for “good reason” within 90 days prior to or 12     
 months following a “change in control.” The payments in this column are “double-trigger” in nature. Because Mr. Segal and Dr. Koehler were terminated prior to the Arrangement, neither will receive cash payments in 
 connection with the Arrangement (other than with respect to any Cash Amount or CVRs they may become eligible to receive in connection with the Arrangement).                                                          |

The cash amounts for Mr. Zinda are calculated as follows:

| Annual Salary ($) |     |     Target Annual 
 Bonus Opportunity 
               ($) |     |     Other 
 Pro-rated 
   Bonuses |     | Cash Severance 
 Multiplier ($) |     |   Total Cash 
 Payments ($) |
| 486,400           |     |           194,560 |     |   360,773 |     |            1.0 |     |    1,041,733 |

| (3) | The amounts in this column represent, for each named executive officer, on a                                                                                                                                                                                                                                                                         
 pre-tax basis, (i) the value of unvested RSUs held by such named executive officer as of November 25, 2025, which will vest upon Closing, and (ii) the spread value of unvested in-the-money Options held by such named executive officer as of November 25, 2025, which will vest upon